FDA designation

WALTHAM, Mass., Feb. 2026 — Partner Therapeutics announced that zenocutuzumab-zbco, an investigational bispecific antibody therapy, has received U.S. FDA...

SAN FRANCISCO, CALIFORNIA | January 26, 2026 — Immusoft, a clinical-stage biotechnology company pioneering engineered B cell therapies, announced...

PHOENIX, August 28, 2025 — Five amniotic membrane allograft products have received official recognition from the FDA’s Tissue Reference...